<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:contributor>S. Ip</dc:contributor>
  <dc:contributor>Jeffrey S. Hall</dc:contributor>
  <dc:contributor>Sean Nashold</dc:contributor>
  <dc:contributor>Katherine Richgels</dc:contributor>
  <dc:contributor>Carrie Alison Smith</dc:contributor>
  <dc:creator>Katrina E. Alger</dc:creator>
  <dc:date>2019</dc:date>
  <dc:description>&lt;div class="NLM_sec NLM_sec_level_1"&gt;&lt;div class="sectionInfo"&gt;&lt;h2 class="sectionHeading"&gt;Introduction:&lt;/h2&gt;&lt;/div&gt;&lt;p&gt;Federal Select Agent Program regulations require laboratories to document a validated procedure for inactivating select agents prior to movement outside registered space. Avian influenza viruses and virulent Newcastle disease virus (vNDV) are cultured in chicken amnio-allantoic fluid (AAF), but the efficacy of commercial lysis buffers to inactivate viruses in protein-rich media has not been documented.&lt;/p&gt;&lt;/div&gt;&lt;div class="NLM_sec NLM_sec_level_1"&gt;&lt;div class="sectionInfo"&gt;&lt;h2 class="sectionHeading"&gt;Objectives:&lt;/h2&gt;&lt;/div&gt;&lt;p&gt;We assesses the efficacy of MagMAX™ lysis buffer for inactivating highly pathogenic avian influenza virus (HPAIV) and vNDV in chicken AAF and confirm the inactivation of avian influenza in serum using heat.&lt;/p&gt;&lt;/div&gt;&lt;div class="NLM_sec NLM_sec_level_1"&gt;&lt;div class="sectionInfo"&gt;&lt;h2 class="sectionHeading"&gt;Methods:&lt;/h2&gt;&lt;/div&gt;&lt;p&gt;Low pathogenic avian influenza virus (LPAIV) and avian paramyxovirus subtype-1 (APMV-1) were incubated with lysis buffer and tested for viability. Known viable LPAIV and APMV-1 RNA was extracted from AAF using MagMAX™-96 AI/ND Viral RNA Isolation kit, and the eluate was tested for remaining infectious agent. Finally, inactivation of LPAIV in serum was examined over 3 combinations of temperature and incubation time.&lt;/p&gt;&lt;/div&gt;&lt;div class="NLM_sec NLM_sec_level_1"&gt;&lt;div class="sectionInfo"&gt;&lt;h2 class="sectionHeading"&gt;Results:&lt;/h2&gt;&lt;/div&gt;&lt;p&gt;MagMAX™ lysis buffer inactivated both LPAIV and APMV-1 in AAF when incubated for 30 minutes at room temperature. The full extraction process eliminated viable virus from the final RNA eluate. LPAIV in serum heated to 70°C for 30 minutes was rendered noninfectious.&lt;/p&gt;&lt;/div&gt;&lt;div class="NLM_sec NLM_sec_level_1"&gt;&lt;div class="sectionInfo"&gt;&lt;h2 class="sectionHeading"&gt;Conclusion:&lt;/h2&gt;&lt;/div&gt;&lt;p&gt;The ability of a diagnostic laboratory to move samples from one space to another is critical to maintaining biosecurity as well as efficient laboratory workflow. Our study demonstrates a method to ensure the inactivation of viable avian influenza and avian paramyxoviruses in AAF, RNA eluate, and viable avian influenza virus in sera.&lt;/p&gt;&lt;/div&gt;</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>10.1177/1535676019888920</dc:identifier>
  <dc:language>en</dc:language>
  <dc:publisher>Sage</dc:publisher>
  <dc:title>Inactivation of viable surrogates for the select agents virulent Newcastle disease virus and highly pathogenic avian influenza virus using either commercial lysis buffer or heat</dc:title>
  <dc:type>article</dc:type>
</oai_dc:dc>